ABSTRACT
Objectives To provide a contemporary nationally representative assessment of atrial fibrillation (AF) and atrial flutter (AFL) expenditures in the United States.
Background AF prevalence is rising over time and management is evolving. However, there has been no contemporary national assessment of expenditures of AF.
Methods Using Medical Expenditure Panel Survey (MEPS) 2016-2021 data, we identified individuals with AF or AFL using International Classification of Disease (ICD)-10 codes and reported total and categorized expenditures. Using two-part and gamma regression models, respectively, we estimated the incremental expenditures with AF for the entire population and for individuals with common coexisting comorbidities. Among individuals with AF, we identified characteristics associated with higher expenditures.
Results Of a weighted surveyed population of 248,067,064 adults, 3,564,763 (1.4%) had AF. Mean age was 71.9 ± 10.6 years and 45.7% were female. Mean unadjusted annual total healthcare expenditure for individuals with AF was $25,451 ± $1,100 compared with $9,254 ± $82 for individuals without AF. The highest spending categories were inpatient visits ($7,975 ± $733) and prescriptions ($6,505 ± $372). AF expenditures increased over the study period by 11.1%. After adjustment, the incremental annual expenditure attributable to AF was $6,188 per person. Incremental expenditures with AF were highest for those with cancer ($11,967, 95% CI $4,410 - $19,525), while AF did not significantly increase expenditures in HF (-$2,756, 95% CI -$10,048 - $4,535). Modified Charlson Comorbidity Index of 1 or ≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditures.
Conclusion AF is associated with substantial healthcare expenditures which are increasing over time. With changes in screening and management, expenditures need periodic reassessments.
Introduction AF prevalence is rising, but contemporary national expenditure assessments are lacking.
Methods Two-part and gamma regression models of MEPS 2016-2021 data (all-payer cross-sectional US survey) estimated AF effect on healthcare expenditures.
Results Of 248,067,064 adults, 1.4% had AF, with mean age 72.1 years and 45.7% female. Mean unadjusted annual expenditure was $25,451 ± $1,100 ($9,254 ± $82 without AF). Incremental adjusted annual expenditure attributable to AF was $6,188. Modified CCI of 1 or ≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditure.
Discussion AF expenditures are substantial and increasing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. See received support from the Yale School of Medicine 2023 Fellowship for Medical Student Research. Dr. Murugiah received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K08HL157727). Dr. Nanna reports research support from the American College of Cardiology (George F and Ann Harris Bellows Foundation), the Patient-Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging/National Institutes of Health (GEMSSTAR award: R03AG074067).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data were openly available prior to the study and continue to be available at: https://meps.ahrq.gov/mepsweb/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support: Dr. See received support from the Yale School of Medicine 2023 Fellowship for Medical Student Research. Dr. Murugiah received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K08HL157727). Dr. Nanna reports research support from the American College of Cardiology (George F and Ann Harris Bellows Foundation), the Patient-Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging/National Institutes of Health (GEMSSTAR award: R03AG074067).
Relationship with Industry: Dr. Freeman reports research support from the NIH/NHLBI and the American College of Cardiology National Cardiovascular Data Registry and advisory board/consulting with Boston Scientific, Medtronic, Abbott, Biosense Webster, and PaceMate. Dr. Nanna reports consulting from HeartFlow, Inc., Novo Nordisk, and Merck.
Data Availability
All data and materials are de-identified and publicly available online at https://meps.ahrq.gov/mepsweb/
Condensed Abstract Abbreviations
- AF
- Atrial Fibrillation
- CCI
- Charlson Comorbidity Index
- MEPS
- Medical Expenditure Panel Survey
- NHEA
- National Health Expenditure Accounts
- US
- United States
Manuscript Abbreviations
- AAD
- Antiarrhythmic Drug
- AF
- Atrial Fibrillation
- AHRQ
- Agency of Healthcare Research and Quality
- ASCVD
- Atherosclerotic Cardiovascular Disease
- CABANA
- Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation
- CCI
- Charlson Comorbidity Index
- COPD
- Chronic Obstructive Pulmonary Disease
- CPI
- Consumer Price Index
- DOAC
- Direct-Acting Oral Anticoagulants
- ED
- Emergency Department
- FPL
- Federal Poverty Line
- GED
- General Educational Development
- HF
- Heart Failure
- HS
- High School
- MEPS
- Medical Expenditure Panel Survey
- NCHS
- National Center for Health Statistics
- NHEA
- National Health Expenditure Accounts
- NHIS
- National Health Interview Survey
- OR
- Odds Ratio
- SD
- Standard Deviation
- US
- United States
- IQR
- Interquartile Range
